Skip to content
Storytelling Co – Lifestyle
Author:
NRG Therapeutics Limited
NRG Therapeutics Announces a PET Biodistribution Trial of Lead Clinical Asset NRG5051
October 21, 2026
NRG Therapeutics Presents Data on Lead Clinical Asset NRG5051 Confirming Novel Disease-Modifying Approach to ALS
August 24, 2026
NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer
August 3, 2026